Bull, Bear & Beyond – Herantis Pharma: executive interview

Herantis Pharma is a Finland-based clinical-stage biotechnology company focused on developing disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases. Its lead programme is HER-096, a peptide therapeutic, which is currently being assessed in a Phase Ib trial for Parkison’s disease (PD). In this interview, Antti Vuolanto, CEO of Herantis, discusses the progress of HER-096 in the clinic to date, the external validation the company has received through grants and non-dilutive funding, as well as the commercial potential of a disease-modifier for PD. He also covers the key catalysts and milestones that investors should watch out for across the next 12–18 months.

Listen on your preferred podcast player below:

• Apple Podcast
• Spotify
• YouTube
• Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.